Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor

04 Jan 2018

The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.

Doors — Door closes, another opens: iTeos upbeat despite Pfizer pact ending • Source: Shutterstock

News that Pfizer Inc. is returning the rights to its indoleamine 2,3-dioxygenase (IDO1) inhibitor is a surprise but represents an opportunity for iTeos Therapeutics SA, according to the Belgian biotech's CEO Michel Detheux.

It has been confirmed this morning (Jan. 4) that the US behemoth has handed back worldwide rights to EOS200271, an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

16 Jun 2025

• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

16 Jun 2025

• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

12 Jun 2025

• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?